Literature DB >> 32080859

Diagnosis and management of hereditary haemochromatosis.

Catherine R Murphree1, Nga N Nguyen1, Vikram Raghunathan1, Sven R Olson1, Thomas DeLoughery1, Joseph J Shatzel1.   

Abstract

Hereditary haemochromatosis, one of the most common genetic disorders in the United States, can produce systemic iron deposition leading to end-organ failure and death if untreated. The diagnosis of this condition can be challenging as elevated serum ferritin may be seen in a variety of conditions, including acute and chronic liver disease, a range of systemic inflammatory states, and both primary and secondary iron overload syndromes. Appropriate and timely diagnosis of haemochromatosis is paramount as simple interventions, such as phlebotomy, can prevent or reverse organ damage from iron overload. The recognition of other aetiologies of elevated ferritin is also vital to ensure that appropriate intervention is provided and phlebotomy only utilized in patients who require it. In this review, we summarize the existing data on the work up and management of hereditary haemochromatosis and present a practical algorithm for the diagnosis and management of this disease.
© 2020 International Society of Blood Transfusion.

Entities:  

Keywords:  blood components; transfusion medicine; transfusion strategy

Mesh:

Year:  2020        PMID: 32080859     DOI: 10.1111/vox.12896

Source DB:  PubMed          Journal:  Vox Sang        ISSN: 0042-9007            Impact factor:   2.144


  3 in total

1.  Association Between Iron Metabolism and Acute Kidney Injury in Critically Ill Patients With Diabetes.

Authors:  Manqiu Mo; Yunqing Gao; Ling Deng; Yuzhen Liang; Ning Xia; Ling Pan
Journal:  Front Endocrinol (Lausanne)       Date:  2022-04-29       Impact factor: 6.055

2.  Disseminated cryptococcosis and hemochromatosis: clues to diagnosis.

Authors:  Larry Nichols; Lindsey Rowley; Ashley Lall
Journal:  Autops Case Rep       Date:  2020-06-05

3.  Haemochromatosis in a kidney transplant recipient: a case report.

Authors:  Izabela Zakrocka; Iwona Baranowicz-Gąszczyk; Wojciech Załuska
Journal:  BMC Nephrol       Date:  2021-05-29       Impact factor: 2.388

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.